A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)
Completed · Phase 2 · Has a placebo group
Conditions studied: Chronic Hepatitis B
In brief
The purpose of this study is to determine if ABI-H0731 given in combination with a standard of care (SOC) entecavir (ETV) is safe and effective in participants with chronic hepatitis B infection (cHBV)
Key facts
- Study ID
- NCT03577171
- Run by
- Assembly Biosciences
- People needed
- 25
- Starts
- 2018-06-19
- Expected to finish
- 2019-06-21
- Last updated by the study team
- 2021-01-28
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Southern California Research Center — Coronado, California, United States
- Asia Pacific Liver Center — Los Angeles, California, United States
- Research and Education — San Diego, California, United States
- Quest Clinical Research — San Francisco, California, United States
- Johns Hopkins University School of Medicine — Baltimore, Maryland, United States
- NYU Langone Health — New York, New York, United States
- Xiaoli Ma MD — Philadelphia, Pennsylvania, United States
- GI Research Institute — Vancouver, British Columbia, Canada
- Toronto Liver Center — Toronto, Ontario, Canada
- University of Hong Kong, Queen Mary Hospital — Hong Kong, Hong Kong
- Waikato Hospital — Hamilton, New Zealand
- King's College London — London, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.